# REFERENCES


1. B. Varalaxmi & N.Srinivas (2015) critical analysis and interpretation of regulatory requirements of active pharmaceutical ingredients (API) dossier In U.S And E.U; International Journal Of Trends In Pharmacy and Life Sciences. 2454-7867

2. Barbara M. Davit and Dale P. Conner (2010) United States of America Generic Drug Product Development; International regulatory requirements for bioequivalence. 978-084937785-3

3. Bhargava NS, et al Comparative study of regulation and registration process of parental product in US and Malaysia; International Journal of Pharmaceutical research scholar. 2277-7873

4. Chung Chow Chan, et al (2014) Challenges to quality and regulatory requirements in the unites states; Drugs, medical device and cell therapy, Therapeutic Drug Solution, First Edition, John Wiley & Sons, Inc.

5. Danial B. Kramer and Arron s. Keselheim (2012) User fees and beyond-the FDA safety and Innovation Act of 2012; The new England Journal of Medicine, prospective.

6. Elizabeth M. Wroe & Philip S. Bonforte (2012) September Sequester Surprise: FDA User Fees on the Chopping Block; Pharmaceutical Law & Industry Report. 1542-9547

7. Frederick R. Ball and Elinor L. Hart (2013) Statutory and Regulatory Controls for Drug Development; Pharmaceutical Law Regulation of Research, Development, and Marketing

8. Garth Behm et al (2013) Development of Generic drug industry in the US after Hatch-waxman Act of 1984; Acta Pharmaceuti a sinica B. 2211-3835

9. Isabel Masanque (2012) FDA Generic Drug User Fee Proposal Aims to Enhance Safety, Access, and Transparency in the Generic Drug Market; Bulletin of health policy law.

10. Jason w. Sapsin, JD, MPH (2014) Introduction to the Regulation of Drugs; The fundamentals of life sciences law: Drugs, devices and Biotech, second edition, 9781630440169.

11. John R. Manthei, Rebecca N. Brandt, And Amy E. Gaither (2012), The Food and Drug Administration Safety and Innovation Act of 2012: Assessing the Impact on the Pharmaceutical and Biotechnology Industries.; Pharmaceutical Law & Industry Report. 1542-9547

12. Johnathan Rickman et al (2013) FDA Exceeds GDUFA Hiring Goal; Washington Drug Letter, 0194-129

**13.** Johnathan Rickman et al (2013) Revised GDUFA Guidance Clarifies Packager & Fatal Flaw Definitions; Washington Drug Letter, 0194-129

**14.** Johnathan Rickman et al (2013) FDA Posts List of Facilities That Have Yet to Pony Up GDUFA Fees**;** Washington Drug Letter, 0194-129

**15.** Johnathan Rickman et al (2013) FDA Denies Small Pharma Company's Request for GDUFA Facility Fee Waiver**;** Washington Drug Letter, 0194-129

**16.** Johnathan Rickman et al (2013) FDA Extends Comment Period on GDUFA Guidance After Website Outage; Washington Drug Letter, 0194-129

**17.** Johnathan Rickman et al (2013) FDA Posts List of Facilities That Have Yet to Pony Up GDUFA Fees**;** Washington Drug Letter, 0194-129

**18.** Jonathan D. Alpern, William M.stauffer and Aron S. Kesselheim, M.D, J. D (2014) High cost generic drugs-implications for patient and policy makers**;** The new England Journal of Medicine, prospective.

**19.** Kelvin outterson, J.D,L.LM (2014) The drug quality and security Act-mind the gaps; The new England Journal of Medicine, prospective.

**20.** Kishor Ahire, et al (2013) A survey based study in current scenario of generic and branded medicines; International Journal of Pharmacy and Pharmaceutical sciences, 0975-1491.

**21.** M. Vassem Akram et al (2014) Regulatory requirements of drug master files by Food and Drug Administration (USA), European medicinal Agency (Europe) and Health Canada and their comparison; Journal of Global Trends in Pharmaceutical sciences. 2230-7346

**22.** Maddela Lakshmi kanth, et al (2015) Advance in the review of generic drug applications by united states Food and Drug administration, A regulatory perspective in the era of GDUFA; International Journal of Drug Regulatory Affairs. 2321-6794

**23.** Nandini Murthy and Richard Morroney History of Food, Drugs and Cosmetic Laws; Fundamentals of US Regulatory Affairs, Seventh Edition.

**24.** Nandini Murthy and Richard Morroney History of FDA and Related Regulated Agencies; Fundamentals of US Regulatory Affairs, Seventh Edition.

**25.** Samrat Sisodia, et al (2013) Opportunities and Challenges Brought by Generic Drug User Fee Act in 2013**;** International Journal of Advanced Research in Pharmaceutical and Bio Sciences. 2277-6222

**26.** Stephen Barlas (2014) Generic Prices Take Flight The FDA Is Struggling to Ground Them; P&T.

**27.** Stephen Barlas (2014) FDA Devotes New Resources to Upgrading Generic Drug Safety But in Some Instances, the Industry Is Pushing Back; P&T

**28.** Stephen Barlas (2012) Congress Is Likely to Approve Generic Drug User Fees Action Should Spur Faster FDA Approvals; P&T

**29.** Ted Seabright and Aaron Kozloff (2014) FDA Releases Draft Guidance on ANDA Content and Format as Efforts Continue to Clarify and Streamline Review Process Under GDUFA**;** International Pharmaceutical Quality, 1937-6898

**30.** Ted Seabright and Aaron Kozloff (2014) Transformation in Industry Practice Must Accompany FDA's Generics**,** International Pharmaceutical Quality, 1937-6898

**31.** Useni Reddy mallu et al (2012) US-FDA generic drug user fees act-a complete review; International Journal of science innovations and discoveries. 2249-5347.

**32.** Useni Reddy mallu et al (2015) API Supplier Change or Addition of Alterate API Supplier in Generic Drug Products: Cost, Quality and Regulatory Factors; Pharmaceutica Analytica Acta. 2153-2435.

**33.** Yu Yu Sachin Gupta (2014) Pioneering advantage in generic drug competition; International Journal of Pharmaceutical and Healthcare Marketing, 1750-6123

**34.** OUTLOOK 2016: (2016) Drug Prices, User Fees, Biosimilars Among Key Topics; Pharmaceutical Law & Industry Report, 1542-9547

**35.** (2015) Biosimilars Policy, Accelerating Medical Breakthroughs Among Year's Key Topics, Pharmaceutical Law & Industry Report, 1542-9547.